1. Anti-infection Cell Cycle/DNA Damage
  2. HIV CRISPR/Cas9
  3. Zidovudine

Zidovudine  (Synonyms: Azidothymidine; AZT; ZDV)

Cat. No.: HY-17413 Purity: 99.95%
SDS COA Handling Instructions Technical Support

Zidovudine is a nucleoside reverse transcriptase inhibitor (NRTI), widely used to treat HIV infection. Zidovudine increases CRISPR/Cas9-mediated editing frequency.

For research use only. We do not sell to patients.

Zidovudine Chemical Structure

Zidovudine Chemical Structure

CAS No. : 30516-87-1

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
100 mg In-stock
500 mg In-stock
1 g   Get quote  
5 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 6 publication(s) in Google Scholar

Other Forms of Zidovudine:

Top Publications Citing Use of Products

View All HIV Isoform Specific Products:

  • Biological Activity

  • Protocol

  • Purity & Documentation

  • References

  • Customer Review

Description

Zidovudine is a nucleoside reverse transcriptase inhibitor (NRTI), widely used to treat HIV infection. Zidovudine increases CRISPR/Cas9-mediated editing frequency.

IC50 & Target[1][2]

HIV-1

 

CRISPR/Cas9

 

Cellular Effect
Cell Line Type Value Description References
143B IC50
12.25 μM
Compound: AZT, Zidovudine
Cytotoxicity against human 143B cells after 72 hrs by MTT assay
Cytotoxicity against human 143B cells after 72 hrs by MTT assay
[PMID: 25440502]
143B IC50
148.42 μM
Compound: AZT, Zidovudine
Cytotoxicity against human thymidine kinase-deficient 143B cells after 72 hrs by MTT assay
Cytotoxicity against human thymidine kinase-deficient 143B cells after 72 hrs by MTT assay
[PMID: 25440502]
5637 IC50
128.82 μM
Compound: AZT
Antiproliferative activity in human 5637 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
Antiproliferative activity in human 5637 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
[PMID: 30108758]
5637 IC50
7 μM
Compound: 1
Cytotoxicity against human 5637 cells assessed as growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human 5637 cells assessed as growth inhibition after 48 hrs by MTT assay
[PMID: 25811955]
A549 IC50
0.011 μM
Compound: AZT
Inhibition of Influenza A virus (A/Viet Nam/1203/2004(H5N1)) hemagglutininin-mediated viral entry into human A549 cells assessed as luciferase activity after 48 hrs postinfection by luminometry
Inhibition of Influenza A virus (A/Viet Nam/1203/2004(H5N1)) hemagglutininin-mediated viral entry into human A549 cells assessed as luciferase activity after 48 hrs postinfection by luminometry
[PMID: 19537689]
A549 IC50
0.012 μM
Compound: AZT
Inhibition of Influenza A virus (A/Bar-headed Goose/Qinghai/59/05(H5N1)) hemagglutininin-mediated viral entry into human A549 cells assessed as luciferase activity after 48 hrs postinfection by luminometry
Inhibition of Influenza A virus (A/Bar-headed Goose/Qinghai/59/05(H5N1)) hemagglutininin-mediated viral entry into human A549 cells assessed as luciferase activity after 48 hrs postinfection by luminometry
[PMID: 19537689]
A549 IC50
11.86 μM
Compound: 3; AZT
Cytotoxicity in human A549 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
Cytotoxicity in human A549 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
[PMID: 31400940]
A549 IC50
16.19 μM
Compound: 13, AZT
Cytotoxicity against human A549 cells after 48 hrs by SRB method
Cytotoxicity against human A549 cells after 48 hrs by SRB method
[PMID: 25933593]
AA5 IC50
< 0.0003 μM
Compound: AZT
Antiviral activity against of Human immunodeficiency virus 1 3B infected in AA5 cells infected with 1.56 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay
Antiviral activity against of Human immunodeficiency virus 1 3B infected in AA5 cells infected with 1.56 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay
[PMID: 20086149]
AA5 IC50
> 0.1 μM
Compound: AZT
Cytotoxicity against human AA5 cells by MTS assay
Cytotoxicity against human AA5 cells by MTS assay
[PMID: 20086149]
AA5 IC50
0.0003 μM
Compound: AZT
Antiviral activity against of Human immunodeficiency virus 1 3B infected in AA5 cells infected with 0.78 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay
Antiviral activity against of Human immunodeficiency virus 1 3B infected in AA5 cells infected with 0.78 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay
[PMID: 20086149]
AA5 IC50
0.0004 μM
Compound: AZT
Antiviral activity against of Human immunodeficiency virus 1 3B infected in AA5 cells infected with 3.13 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay
Antiviral activity against of Human immunodeficiency virus 1 3B infected in AA5 cells infected with 3.13 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay
[PMID: 20086149]
AA5 IC50
0.006 μM
Compound: AZT
Antiviral activity against Human immunodeficiency virus 1 3B infected in AA5 cells infected with 0.78 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA
Antiviral activity against Human immunodeficiency virus 1 3B infected in AA5 cells infected with 0.78 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA
[PMID: 20086149]
AA5 IC50
0.008 μM
Compound: AZT
Antiviral activity against Human immunodeficiency virus 1 3B infected in AA5 cells infected with 3.13 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA
Antiviral activity against Human immunodeficiency virus 1 3B infected in AA5 cells infected with 3.13 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA
[PMID: 20086149]
AA5 IC50
0.009 μM
Compound: AZT
Antiviral activity against Human immunodeficiency virus 1 3B infected in AA5 cells infected with 1.56 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA
Antiviral activity against Human immunodeficiency virus 1 3B infected in AA5 cells infected with 1.56 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA
[PMID: 20086149]
B(EBV+) EC50
0.001 μM
Compound: AZT
Effective concentration required for antiviral activity against B(EBV+) cell line of AA5 cells of Human by XTT assay
Effective concentration required for antiviral activity against B(EBV+) cell line of AA5 cells of Human by XTT assay
[PMID: 7932526]
Bel-7402 EC50
4.62 μM
Compound: Zidovudine
Cytotoxicity against human Bel7402 cells after 48 hrs by MTT assay
Cytotoxicity against human Bel7402 cells after 48 hrs by MTT assay
[PMID: 18313175]
Bone marrow cell CC50
0.5 μM
Compound: ZDV, AZT
Cytotoxicity against human bone marrow cells after 24 hrs by BFU-E assay
Cytotoxicity against human bone marrow cells after 24 hrs by BFU-E assay
[PMID: 20439609]
Bone marrow cell CC50
0.89 μM
Compound: ZDV, AZT
Cytotoxicity against human bone marrow cells after 24 hrs by GM-CFU assay
Cytotoxicity against human bone marrow cells after 24 hrs by GM-CFU assay
[PMID: 20439609]
BxT EC50
0.055 μM
Compound: AZT
Effective concentration required for antiviral activity against BxT cell line of 174xCEM cells of Human by XTT assay
Effective concentration required for antiviral activity against BxT cell line of 174xCEM cells of Human by XTT assay
[PMID: 7932526]
C3H/3T3 EC50
0.02 μM
Compound: AZT
Concentration of compound required to inhibit HIV-1 induced cytopathogenicity of MSV-induced transformation of C3H/3T3 cells by 50%.
Concentration of compound required to inhibit HIV-1 induced cytopathogenicity of MSV-induced transformation of C3H/3T3 cells by 50%.
[PMID: 2016718]
C8166 CC50
> 1 μM
Compound: AZT
Cytotoxicity against C8166 cells by MTT assay
Cytotoxicity against C8166 cells by MTT assay
[PMID: 16279773]
C8166 CC50
> 100 μg/mL
Compound: AZT
Cytotoxicity against HIV1 infected human C8166-CCR5 cells assessed as decrease in cell viability by cell associated dehydrogenase activity assay
Cytotoxicity against HIV1 infected human C8166-CCR5 cells assessed as decrease in cell viability by cell associated dehydrogenase activity assay
[PMID: 19515569]
C8166 CC50
> 1000 μM
Compound: AZT
Cytotoxicity against human C8166 cells by MTT assay
Cytotoxicity against human C8166 cells by MTT assay
[PMID: 19413342]
C8166 CC50
> 1000 μM
Compound: 1
Concentration which reduces the viability of uninfected C8166 cells by 50%
Concentration which reduces the viability of uninfected C8166 cells by 50%
10.1016/0960-894X(96)00446-5
C8166 CC50
> 1000 μM
Compound: AZT
Concentration of compound required to reduce viability of C8166 cells by 50%.
Concentration of compound required to reduce viability of C8166 cells by 50%.
10.1016/0960-894X(96)00444-1
C8166 CC50
> 200 μg/mL
Compound: AZT
Cytotoxicity against human C8166 cells assessed as inhibition of cell viability after 3 days by MTT assay
Cytotoxicity against human C8166 cells assessed as inhibition of cell viability after 3 days by MTT assay
[PMID: 23368966]
C8166 CC50
> 200 μg/mL
Compound: AZT
Cytotoxicity against C8166 cells after 72 hrs by MTT method
Cytotoxicity against C8166 cells after 72 hrs by MTT method
[PMID: 17489633]
C8166 CC50
> 200 μg/mL
Compound: AZT
Cytotoxicity against human C8166 cells by MTT assay
Cytotoxicity against human C8166 cells by MTT assay
[PMID: 23327759]
C8166 CC50
> 200 μg/mL
Compound: AZT
Cytotoxicity against human C8166 cells by MTT assay
Cytotoxicity against human C8166 cells by MTT assay
[PMID: 23078294]
C8166 CC50
> 200 μg/mL
Compound: AZT
Cytotoxicity against human C8166 cells by MTT assay
Cytotoxicity against human C8166 cells by MTT assay
[PMID: 20146529]
C8166 CC50
> 200 μg/mL
Compound: AZT
Cytotoxicity against human C8166 cells by MTT method
Cytotoxicity against human C8166 cells by MTT method
[PMID: 18088099]
C8166 CC50
> 200 μg/mL
Compound: AZT
Cytotoxicity against human C8166 cells by MTT method
Cytotoxicity against human C8166 cells by MTT method
[PMID: 16643044]
C8166 CC50
> 200 μg/mL
Compound: AZT
Cytotoxicity against human C8166 cells by MTT assay
Cytotoxicity against human C8166 cells by MTT assay
[PMID: 16499331]
C8166 CC50
> 200 μM
Compound: AZT
Cytotoxicity against human C8166 cells after 3 days by MTT assay
Cytotoxicity against human C8166 cells after 3 days by MTT assay
[PMID: 23738539]
C8166 CC50
> 749 μM
Compound: AZT, zidovudine
Cytotoxicity against human C8166 cells after 72 hrs by MTT method
Cytotoxicity against human C8166 cells after 72 hrs by MTT method
[PMID: 18316190]
C8166 EC50
0.00152 μM
Compound: AZT; zidovudine
Antiviral activity against HIV1 74V infected in human C8166 cells assessed as reduction in p24 antigen level incubated for 4 hrs followed by cell plating for 72 hrs by ELISA method
Antiviral activity against HIV1 74V infected in human C8166 cells assessed as reduction in p24 antigen level incubated for 4 hrs followed by cell plating for 72 hrs by ELISA method
[PMID: 27039251]
C8166 EC50
0.0019 μM
Compound: AZT
Antiviral activity against HIV1 3B infected human C8166 cells assessed as inhibition of syncytia formation by p24 antigen based assay
Antiviral activity against HIV1 3B infected human C8166 cells assessed as inhibition of syncytia formation by p24 antigen based assay
[PMID: 19170521]
C8166 EC50
0.0034 μg/mL
Compound: AZT
Antiviral activity against HIV1 in C8166 cells after 72 hrs
Antiviral activity against HIV1 in C8166 cells after 72 hrs
[PMID: 18088099]
C8166 IC50
0.004 μM
Compound: AZT
Antiviral activity was evaluated by inhibition of HIV-1 replication in CD4+ lymphoblastoid cell line infected with HIV/IIIB strain
Antiviral activity was evaluated by inhibition of HIV-1 replication in CD4+ lymphoblastoid cell line infected with HIV/IIIB strain
10.1016/0960-894X(95)00257-T
C8166 EC50
0.00436 μM
Compound: AZT; zidovudine
Antiviral activity against HIV1 3B infected in human C8166 cells assessed as reduction in p24 antigen level incubated for 2 hrs followed by cell plating for 72 hrs by ELISA method
Antiviral activity against HIV1 3B infected in human C8166 cells assessed as reduction in p24 antigen level incubated for 2 hrs followed by cell plating for 72 hrs by ELISA method
[PMID: 27039251]
C8166 EC50
0.00794 μM
Compound: AZT; zidovudine
Antiviral activity against HIV1 3B infected in human C8166 cells assessed as cytopathic effect by counting the number of syncytia by microscopy
Antiviral activity against HIV1 3B infected in human C8166 cells assessed as cytopathic effect by counting the number of syncytia by microscopy
[PMID: 27039251]
C8166 EC50
0.00812 μM
Compound: AZT
Antiviral activity against 0.06 MOI Human immunodeficiency virus 1 IIIB A17 harboring reverse transcriptase K103N and Y181C double mutant infected in C8166 cells assessed as reduction in virus-induced cytopathic effect after 3 days by syncytium reduction
Antiviral activity against 0.06 MOI Human immunodeficiency virus 1 IIIB A17 harboring reverse transcriptase K103N and Y181C double mutant infected in C8166 cells assessed as reduction in virus-induced cytopathic effect after 3 days by syncytium reduction
[PMID: 21689939]
C8166 EC50
0.0087 μM
Compound: AZT
Antiviral activity against HIV-1 3B infected in C8166 cells assessed as virus-induced cytopathic effect measuring scintia formation after 3 days by microscopy
Antiviral activity against HIV-1 3B infected in C8166 cells assessed as virus-induced cytopathic effect measuring scintia formation after 3 days by microscopy
[PMID: 23046280]
C8166 EC50
0.0108 μM
Compound: AZT
Antiviral activity against HIV1 in human C8166 cells assessed as protection against viral-induced cytopathic effect by syncytium reduction assay
Antiviral activity against HIV1 in human C8166 cells assessed as protection against viral-induced cytopathic effect by syncytium reduction assay
[PMID: 18396905]
C8166 EC50
0.011 μM
Compound: AZT, zidovudine
Antiviral activity against HIV1 3B in C8166 cells by syncytium reduction assay
Antiviral activity against HIV1 3B in C8166 cells by syncytium reduction assay
[PMID: 18316190]
C8166 EC50
0.0128 μM
Compound: AZT
Antiviral activity against wild type HIV1 3B infected in human C8166 cells assessed as inhibition of viral-induced cytopathogenicity after 3 days by syncytium formation assay
Antiviral activity against wild type HIV1 3B infected in human C8166 cells assessed as inhibition of viral-induced cytopathogenicity after 3 days by syncytium formation assay
[PMID: 21788138]
C8166 EC50
0.013 μM
Compound: Zidovudine
Antiviral activity against HIV1 3B infected in human C8166 cells assessed as inhibition of viral-induced cytopathic effect by measuring syncytia formation after 72 hrs by inverted microscopic method
Antiviral activity against HIV1 3B infected in human C8166 cells assessed as inhibition of viral-induced cytopathic effect by measuring syncytia formation after 72 hrs by inverted microscopic method
[PMID: 27894873]
C8166 EC50
0.016 μg/mL
Compound: AZT
Antiviral activity against HIV1 MN infected in human C8166 cells assessed as reduction in antigen gp120 production by ELISA
Antiviral activity against HIV1 MN infected in human C8166 cells assessed as reduction in antigen gp120 production by ELISA
[PMID: 11374977]
C8166 EC50
0.016 μM
Compound: AZT
Tested against HIV-1 111B for Inhibition of viral replication by determining reduction of syncytia formation and antigen gp120 in C8166 cells, estimated by ELISA
Tested against HIV-1 111B for Inhibition of viral replication by determining reduction of syncytia formation and antigen gp120 in C8166 cells, estimated by ELISA
10.1016/S0960-894X(97)00022-X
C8166 EC50
0.017 μM
Compound: AZT
Antiviral activity against on HIV1 3b infected C8166 cells assessed as syncytial cell formation after 3 days
Antiviral activity against on HIV1 3b infected C8166 cells assessed as syncytial cell formation after 3 days
[PMID: 17291043]
C8166 EC50
0.019 μM
Compound: AZT
Antiviral activity against HIV1 3B infected in human C8166 cells assessed as inhibition of syncytia after 3 days
Antiviral activity against HIV1 3B infected in human C8166 cells assessed as inhibition of syncytia after 3 days
[PMID: 23099098]
C8166 EC50
0.02 μM
Compound: AZT
Antiviral activity against HIV1 3B infected in human C8166 cells assessed as inhibition of viral-induced cytopathogenicity by syncytium formation assay
Antiviral activity against HIV1 3B infected in human C8166 cells assessed as inhibition of viral-induced cytopathogenicity by syncytium formation assay
[PMID: 24299567]
C8166 EC50
0.0228 μM
Compound: AZT
Antiviral activity against HIV1 A17 harbouring RT K103N/Y181C mutant infected in human C8166 cells assessed as protection against virus-induced cytopathic effect after 3 days by syncytium reduction assay
Antiviral activity against HIV1 A17 harbouring RT K103N/Y181C mutant infected in human C8166 cells assessed as protection against virus-induced cytopathic effect after 3 days by syncytium reduction assay
[PMID: 23164656]
C8166 EC50
0.023 μM
Compound: AZT
Antiviral activity against wild type HIV1 A17 harboring reverse transcriptase K103N and Y181C mutant infected in human C8166 cells assessed as inhibition of viral-induced cytopathogenicity after 3 days by syncytium formation assay
Antiviral activity against wild type HIV1 A17 harboring reverse transcriptase K103N and Y181C mutant infected in human C8166 cells assessed as inhibition of viral-induced cytopathogenicity after 3 days by syncytium formation assay
[PMID: 21788138]
C8166 EC50
0.023 μM
Compound: AZT
Antiviral activity against HIV1 A17 expressing reverse transcriptase K103N/Y181C double mutant infected in human C8166 cells assessed as protection against virus-induced cytopathogenicity after 3 days by measuring syncytia under inverted microscope
Antiviral activity against HIV1 A17 expressing reverse transcriptase K103N/Y181C double mutant infected in human C8166 cells assessed as protection against virus-induced cytopathogenicity after 3 days by measuring syncytia under inverted microscope
[PMID: 21719299]
C8166 EC50
0.03 μM
Compound: AZT
Concentration required to inhibit p24 viral antigen production by 50% in C-8166 cells
Concentration required to inhibit p24 viral antigen production by 50% in C-8166 cells
10.1016/0960-894X(95)00208-B
C8166 EC50
0.034 μg/mL
Compound: AZT
Antiviral activity against HIV-1 3B infected in human C8166 cells assessed as inhibition of syncytia formation after 3 days
Antiviral activity against HIV-1 3B infected in human C8166 cells assessed as inhibition of syncytia formation after 3 days
[PMID: 23368966]
C8166 EC50
0.034 μM
Compound: AZT
Antiviral activity against HIV-1 3B infected in human C8166 cells assessed as inhibition of virus-induced cytopathic effect after 3 days by Syncytia Assay
Antiviral activity against HIV-1 3B infected in human C8166 cells assessed as inhibition of virus-induced cytopathic effect after 3 days by Syncytia Assay
[PMID: 23738539]
C8166 EC50
0.1293 μM
Compound: AZT
Antiviral activity against Human immunodeficiency virus 2 ROD infected in C8166 cells assessed as reduction in virus-induced cytopathic effect after 3 days by syncytium reduction assay
Antiviral activity against Human immunodeficiency virus 2 ROD infected in C8166 cells assessed as reduction in virus-induced cytopathic effect after 3 days by syncytium reduction assay
[PMID: 21689939]
C8166 EC50
10.59 nM
Compound: AZT
Antiviral activity against 0.06 MOI Human immunodeficiency virus 1 IIIB infected in C8166 cells assessed as reduction in virus-induced cytopathic effect after 3 days by syncytium reduction assay
Antiviral activity against 0.06 MOI Human immunodeficiency virus 1 IIIB infected in C8166 cells assessed as reduction in virus-induced cytopathic effect after 3 days by syncytium reduction assay
[PMID: 21689939]
C8166 CC50
1139.47 μg/mL
Compound: AZT
Cytotoxicity against human C8166 cells after 3 days by MTT assay
Cytotoxicity against human C8166 cells after 3 days by MTT assay
[PMID: 20488700]
C8166 CC50
1145 μg/mL
Compound: AZT
Cytotoxicity against human C8166 cells after 3 days by MTT assay
Cytotoxicity against human C8166 cells after 3 days by MTT assay
[PMID: 20598530]
C8166 EC50
12.8 nM
Compound: AZT
Antiviral activity against wild type HIV1 3B infected in human C8166 cells assessed as protection against virus-induced cytopathic effect after 3 days by syncytium reduction assay
Antiviral activity against wild type HIV1 3B infected in human C8166 cells assessed as protection against virus-induced cytopathic effect after 3 days by syncytium reduction assay
[PMID: 23164656]
C8166 EC50
12.82 nM
Compound: AZT
Antiviral activity against wild-type HIV1 3B infected in human C8166 cells assessed as protection against virus-induced cytopathogenicity after 3 days by measuring syncytia under inverted microscope
Antiviral activity against wild-type HIV1 3B infected in human C8166 cells assessed as protection against virus-induced cytopathogenicity after 3 days by measuring syncytia under inverted microscope
[PMID: 21719299]
C8166 CC50
200 μg/mL
Compound: AZT
Cytotoxicity against human C8166 cells by MTT assay
Cytotoxicity against human C8166 cells by MTT assay
[PMID: 19685905]
C8166 EC50
39 μM
Compound: AZT
Antiviral activity against HIV2 ROD infected in human C8166 cells assessed as protection against virus-induced cytopathic effect after 3 days by syncytium reduction assay
Antiviral activity against HIV2 ROD infected in human C8166 cells assessed as protection against virus-induced cytopathic effect after 3 days by syncytium reduction assay
[PMID: 23164656]
C8166 EC50
39 μM
Compound: AZT
Antiviral activity against HIV-2 ROD infected in human C8166 cells assessed as protection against viral cytopathogenicity after 3 days by measuring syncytia under inverted microscope
Antiviral activity against HIV-2 ROD infected in human C8166 cells assessed as protection against viral cytopathogenicity after 3 days by measuring syncytia under inverted microscope
[PMID: 21719299]
C8166 CC50
3987.58 μM
Compound: AZT
Cytotoxicity against human C8166 cells assessed as reduction in cell viability incubated for 3 days by MTT assay
Cytotoxicity against human C8166 cells assessed as reduction in cell viability incubated for 3 days by MTT assay
[PMID: 34812640]
C8166 CC50
4.07 μM
Compound: AZT
Cytotoxicity against human C8166 cells by MTT assay
Cytotoxicity against human C8166 cells by MTT assay
[PMID: 21650224]
C8166 CC50
4.07 μM
Compound: AZT
Cytotoxicity against human C8166 cells by MTT assay
Cytotoxicity against human C8166 cells by MTT assay
[PMID: 21534540]
C8166 EC50
4.5 nM
Compound: AZT
Antiviral activity against Human immunodeficiency virus 1 3B infected in human C8166 cells assessed as numbers of syncytia after 3 days by MTT assay
Antiviral activity against Human immunodeficiency virus 1 3B infected in human C8166 cells assessed as numbers of syncytia after 3 days by MTT assay
[PMID: 21561060]
C8166 CC50
4071.9 μM
Compound: AZT
Cytotoxicity against human C8166 cells after 3 days by MTT assay
Cytotoxicity against human C8166 cells after 3 days by MTT assay
[PMID: 21561060]
C8166 CC50
4107.39 μM
Compound: AZT
Cytotoxicity against human C8166 cells after 3 days by MTT assay
Cytotoxicity against human C8166 cells after 3 days by MTT assay
[PMID: 23046280]
C8166 CC50
4552.1 μM
Compound: AZT
Cytotoxicity against C8166 cells by MTT method
Cytotoxicity against C8166 cells by MTT method
[PMID: 17291043]
C8166 CC50
4676.07 μM
Compound: AZT; zidovudine
Cytotoxicity against human C8166 cells after 72 hrs by MTT assay
Cytotoxicity against human C8166 cells after 72 hrs by MTT assay
[PMID: 27039251]
C8166 CC50
4690 μM
Compound: AZT
Cytotoxicity against human C8166 cells by MTT assay
Cytotoxicity against human C8166 cells by MTT assay
[PMID: 26214125]
C8166 CC50
4913.8 μM
Compound: AZT
Cytotoxicity against human C8166 cells assessed as decrease in cell viability by MTT assay
Cytotoxicity against human C8166 cells assessed as decrease in cell viability by MTT assay
[PMID: 23164656]
C8166 CC50
5041 μM
Compound: AZT
Antiviral activity against HIV1 3B infected in human C8166 cells assessed as protection against virus-induced cytopathogenicity after 3 days
Antiviral activity against HIV1 3B infected in human C8166 cells assessed as protection against virus-induced cytopathogenicity after 3 days
[PMID: 21194939]
C8166 CC50
5091 μM
Compound: AZT
Cytotoxicity against human C8166 cells after 72 hrs by MTT assay
Cytotoxicity against human C8166 cells after 72 hrs by MTT assay
[PMID: 18396905]
C8166 CC50
5110 μM
Compound: AZT
Cytotoxicity against human C8166 cells after 3 days by MTT assay
Cytotoxicity against human C8166 cells after 3 days by MTT assay
[PMID: 23099098]
C8166 CC50
5231.6 μM
Compound: AZT
Cytotoxicity against human C8166 cells after 72 hrs by MTT assay
Cytotoxicity against human C8166 cells after 72 hrs by MTT assay
[PMID: 30596489]
C8166 CC50
5401.4 μM
Compound: AZT
Cytotoxicity against human C8166 cells by MTT assay
Cytotoxicity against human C8166 cells by MTT assay
[PMID: 21788138]
C8166 CC50
5401.4 μM
Compound: AZT
Cytotoxicity against human C8166 cells by MTT colorimetric assay
Cytotoxicity against human C8166 cells by MTT colorimetric assay
[PMID: 21719299]
C8166 CC50
5601.71 μM
Compound: AZT
Cytotoxicity against human C8166 cells by MTT assay
Cytotoxicity against human C8166 cells by MTT assay
[PMID: 21689939]
C8166 CC50
5746.1 μM
Compound: AZT
Cytotoxicity against C8166 cells by MTT assay
Cytotoxicity against C8166 cells by MTT assay
[PMID: 17315963]
C8166 CC50
5858.85 μM
Compound: Zidovudine
Cytotoxicity against human C8166 cells measured after 72 hrs by MTT assay
Cytotoxicity against human C8166 cells measured after 72 hrs by MTT assay
[PMID: 27894873]
Caco-2 IC50
0.006 mg/mL
Compound: AZT
Antiviral activity against rotavirus RF infected human Caco-2 cells following viral attachment after 72 hrs
Antiviral activity against rotavirus RF infected human Caco-2 cells following viral attachment after 72 hrs
[PMID: 17337193]
Caco-2 IC50
0.015 mg/mL
Compound: AZT
Growth inhibition of human Caco-2 cells after 72 hrs
Growth inhibition of human Caco-2 cells after 72 hrs
[PMID: 17079149]
Caco-2 IC50
0.015 mg/mL
Compound: AZT
Cytotoxicity against human Caco-2 cells after 72 hrs
Cytotoxicity against human Caco-2 cells after 72 hrs
[PMID: 17079149]
Caco-2 IC50
22.39 μM
Compound: AZT
Antiviral activity against Rotavirus RF in human Caco-2 cells assessed as inhibition of infectivity following virus attachment after 72 hrs
Antiviral activity against Rotavirus RF in human Caco-2 cells assessed as inhibition of infectivity following virus attachment after 72 hrs
[PMID: 17555969]
Caco-2 IC50
22.45 μM
Compound: AZT
Antiviral activity against rotavirus RF in human Caco-2 cells assessed as inhibition of infectivity following virus attachment after 72 hrs
Antiviral activity against rotavirus RF in human Caco-2 cells assessed as inhibition of infectivity following virus attachment after 72 hrs
[PMID: 18037195]
Caco-2 IC50
22.45 μM
Compound: AZT
Antiviral activity against rotavirus RF infected human Caco-2 cells following viral attachment after 72 hrs
Antiviral activity against rotavirus RF infected human Caco-2 cells following viral attachment after 72 hrs
[PMID: 17337193]
Caco-2 CC50
56.1 μM
Compound: AZT
Cytotoxicity against human Caco-2 cells after 72 hrs
Cytotoxicity against human Caco-2 cells after 72 hrs
[PMID: 18037195]
Caco-2 CC50
56.1 μM
Compound: AZT
Cytotoxicity against human Caco-2 cells after 72 hrs
Cytotoxicity against human Caco-2 cells after 72 hrs
[PMID: 17548129]
Caco-2 IC50
74.62 μM
Compound: AZT
Antiviral activity against Rotavirus RF in human Caco-2 cells assessed as neutralization of virus in solution before its attachment after 72 hrs
Antiviral activity against Rotavirus RF in human Caco-2 cells assessed as neutralization of virus in solution before its attachment after 72 hrs
[PMID: 17555969]
Caco-2 IC50
74.84 μM
Compound: AZT
Antiviral activity against rotavirus RF in human Caco-2 cells assessed as neutralization of virus before its attachment after 72 hrs
Antiviral activity against rotavirus RF in human Caco-2 cells assessed as neutralization of virus before its attachment after 72 hrs
[PMID: 18037195]
CCRF-CEM EC50
< 0.001 μM
Compound: AZT
Effective concentration of required to inhibit the replication of HIV-1 BY 50% in CEM cells
Effective concentration of required to inhibit the replication of HIV-1 BY 50% in CEM cells
[PMID: 11170632]
CCRF-CEM CC50
> 100 μg/mL
Compound: AZT
Cytotoxic concentration which is required to reduce human CEM cell viability by 50%.
Cytotoxic concentration which is required to reduce human CEM cell viability by 50%.
[PMID: 9046339]
CCRF-CEM IC50
> 100 μM
Compound: 27, L-AZT
Cytotoxicity against human CEM cells after 6 days by trypan blue exclusion assay
Cytotoxicity against human CEM cells after 6 days by trypan blue exclusion assay
[PMID: 21700368]
CCRF-CEM CC50
> 100 μM
Compound: 1b; AZT
Cytotoxicity in human CEM/0 cells assessed as reduction in cell viability incubated for 4 to 5 days
Cytotoxicity in human CEM/0 cells assessed as reduction in cell viability incubated for 4 to 5 days
[PMID: 32515595]
CCRF-CEM EC50
> 100 μM
Compound: 3 (AZT)
Compound was evaluated for the inhibition of HIV replication using HIV-2 infected CEM-TK- cells.
Compound was evaluated for the inhibition of HIV replication using HIV-2 infected CEM-TK- cells.
10.1016/0960-894X(96)00195-3
CCRF-CEM CC50
> 100 μM
Compound: AZT
Cytotoxic concentration required to reduce the viability of HIV-1 by 50% in CEM/TK cells
Cytotoxic concentration required to reduce the viability of HIV-1 by 50% in CEM/TK cells
[PMID: 12593658]
CCRF-CEM EC50
> 100 μM
Compound: AZT
Effective concentration required to inhibit the replication of HIV-1 by 50% in CEM/TK cells
Effective concentration required to inhibit the replication of HIV-1 by 50% in CEM/TK cells
[PMID: 12593658]
CCRF-CEM CC50
> 125 μg/mL
Compound: zidovudine
Cytotoxic concentration required to reduce CEM cell viability by 50%
Cytotoxic concentration required to reduce CEM cell viability by 50%
[PMID: 8709116]
CCRF-CEM CC50
> 250 μM
Compound: AZT
Cytotoxicity against human CEM/0 cells assessed as reduction in cell proliferation incubated for 4 to 5 days
Cytotoxicity against human CEM/0 cells assessed as reduction in cell proliferation incubated for 4 to 5 days
[PMID: 26125628]
CCRF-CEM CC50
> 250 μM
Compound: AZT
Concentration of compound required to reduce viability of CEM/0 cells by 50%.
Concentration of compound required to reduce viability of CEM/0 cells by 50%.
10.1016/0960-894X(96)00444-1
CCRF-CEM CC50
> 250 μM
Compound: AZT
Concentration required to reduce cell viability of CEM/0 cells by 50%
Concentration required to reduce cell viability of CEM/0 cells by 50%
10.1016/0960-894X(96)00443-X
CCRF-CEM CC50
> 500 μM
Compound: AZT
Concentration required to reduce CEM/0 cell viability by 50%
Concentration required to reduce CEM/0 cell viability by 50%
[PMID: 11356105]
CCRF-CEM IC50
0.003 μg/mL
Compound: AZT
compound tested for inhibitory activity by plaque reduction assay against HIV-1 in CEM cells
compound tested for inhibitory activity by plaque reduction assay against HIV-1 in CEM cells
[PMID: 9548818]
CCRF-CEM EC50
0.003 μM
Compound: n AZT
Effective concentration required to inhibit HIV-1 induced cytopathicity by 50% in CEM cells
Effective concentration required to inhibit HIV-1 induced cytopathicity by 50% in CEM cells
[PMID: 11714616]
CCRF-CEM EC50
0.004 μM
Compound: n AZT
Effective concentration required to inhibit HIV-2 induced cytopathicity by 50% in CEM cells
Effective concentration required to inhibit HIV-2 induced cytopathicity by 50% in CEM cells
[PMID: 11714616]
CCRF-CEM EC50
0.005 μM
Compound: 3 (AZT)
Compound was evaluated for the inhibition of HIV replication using HIV-1 infected CEM cells.
Compound was evaluated for the inhibition of HIV replication using HIV-1 infected CEM cells.
10.1016/0960-894X(96)00195-3
CCRF-CEM EC50
0.006 μM
Compound: AZT
Concentration required to protect CEM/0 cells against the cytopathicity of HIV-2 by 50%.
Concentration required to protect CEM/0 cells against the cytopathicity of HIV-2 by 50%.
[PMID: 11356105]
CCRF-CEM EC50
0.0064 μM
Compound: AZT
Concentration required to protect CEM/0 cells against the cytopathicity of HIV-1 by 50%.
Concentration required to protect CEM/0 cells against the cytopathicity of HIV-1 by 50%.
[PMID: 11356105]
CCRF-CEM EC50
0.008 μM
Compound: 3 (AZT)
Compound was evaluated for the inhibition of HIV replication using HIV-2 infected CEM cells.
Compound was evaluated for the inhibition of HIV replication using HIV-2 infected CEM cells.
10.1016/0960-894X(96)00195-3
CCRF-CEM EC50
0.012 μM
Compound: 4, AZT
Antiviral activity against HIV1 3B infected in human CEM cells assessed as virus-induced giant cell formation after 4 days by microscopic analysis
Antiviral activity against HIV1 3B infected in human CEM cells assessed as virus-induced giant cell formation after 4 days by microscopic analysis
[PMID: 24177359]
CCRF-CEM EC50
0.067 μM
Compound: 4, AZT
Antiviral activity against HIV2 ROD infected in human CEM cells assessed as virus-induced giant cell formation after 4 days by microscopic analysis
Antiviral activity against HIV2 ROD infected in human CEM cells assessed as virus-induced giant cell formation after 4 days by microscopic analysis
[PMID: 24177359]
CCRF-CEM ED50
0.12 μM
Compound: AZT
Concentration that reduced by 50% the HIV induced CPE (cytopathic effect) on day 11.
Concentration that reduced by 50% the HIV induced CPE (cytopathic effect) on day 11.
[PMID: 1712047]
CCRF-CEM ED50
0.12 μM
Compound: AZT
Concentration that reduced by 50% the HIV induced CPE (cytopathic effect) on day 7.
Concentration that reduced by 50% the HIV induced CPE (cytopathic effect) on day 7.
[PMID: 1712047]
CCRF-CEM ED50
0.18 μM
Compound: AZT
Concentration that reduced by 50% the HIV induced CPE (cytopathic effect) on day 19.
Concentration that reduced by 50% the HIV induced CPE (cytopathic effect) on day 19.
[PMID: 1712047]
CCRF-CEM ED50
0.45 μM
Compound: AZT
Concentration that reduced by 50% the HIV induced CPE (cytopathic effect) on day 22.
Concentration that reduced by 50% the HIV induced CPE (cytopathic effect) on day 22.
[PMID: 1712047]
CCRF-CEM EC50
0.7 μM
Compound: AZT
Cytotoxicity against african human CEM cells after 6 days by XTT assay
Cytotoxicity against african human CEM cells after 6 days by XTT assay
[PMID: 20691339]
CCRF-CEM IC50
1.04 μM
Compound: AZT
Antiviral activity against Human immunodeficiency virus 1 NL4.3 infected human CEM cells expressing GFP measured up to 8 days postinfection by p24 antigen capture ELISA
Antiviral activity against Human immunodeficiency virus 1 NL4.3 infected human CEM cells expressing GFP measured up to 8 days postinfection by p24 antigen capture ELISA
[PMID: 20350812]
CCRF-CEM EC50
1.05 μM
Compound: AZT
Antiviral activity against 0.05 MOI Human immunodeficiency virus 1 NL4.3 infected in human CEM cells expressing green fluorescent protein assessed as p24 antigen production measured 7 days post infection by ELISA
Antiviral activity against 0.05 MOI Human immunodeficiency virus 1 NL4.3 infected in human CEM cells expressing green fluorescent protein assessed as p24 antigen production measured 7 days post infection by ELISA
[PMID: 21295891]
CCRF-CEM IC50
1.05 μM
Compound: AZT
Antiviral activity against HIV1 NL4-3 infected in GFP expressing human CEM cells assessed as inhibition of viral infection measured after 9 days postinfection by microfluorometry
Antiviral activity against HIV1 NL4-3 infected in GFP expressing human CEM cells assessed as inhibition of viral infection measured after 9 days postinfection by microfluorometry
[PMID: 20137956]
CCRF-CEM EC50
1.1 μM
Compound: AZT
Antiviral activity against HIV1 NL4.3 infected in human CEM-GFP T cells assessed as inhibition of p24 antigen production after 7 days by ELISA
Antiviral activity against HIV1 NL4.3 infected in human CEM-GFP T cells assessed as inhibition of p24 antigen production after 7 days by ELISA
[PMID: 21227704]
CCRF-CEM IC50
13 μM
Compound: AZT
Compound was evaluated for its toxicity by Calorimetric assay in CEM
Compound was evaluated for its toxicity by Calorimetric assay in CEM
[PMID: 9357530]
CCRF-CEM IC50
14.3 μM
Compound: AZT
Cytotoxicity against human CEM cells after 3 days by MTT assay
Cytotoxicity against human CEM cells after 3 days by MTT assay
[PMID: 19153047]
CCRF-CEM IC50
14.3 μM
Compound: AZT
Cytotoxicity against human CEM cells after 6 days by trypan blue exclusion assay
Cytotoxicity against human CEM cells after 6 days by trypan blue exclusion assay
[PMID: 21700368]
CCRF-CEM IC50
14.3 μM
Compound: AZT
Cytotoxicity against human CEM cells assessed as reduction in cell viability after 5 days by Cell Titer 96 Aqueous One Solution cell proliferation assay
Cytotoxicity against human CEM cells assessed as reduction in cell viability after 5 days by Cell Titer 96 Aqueous One Solution cell proliferation assay
[PMID: 25701249]
CCRF-CEM IC50
14.3 μM
Compound: AZT
Cytotoxicity against human CEM cells after 5 days
Cytotoxicity against human CEM cells after 5 days
[PMID: 19948402]
CCRF-CEM IC50
14.3 μM
Compound: AZT
Cytotoxicity against human CEM cells after 6 days by trypan blue exclusion method
Cytotoxicity against human CEM cells after 6 days by trypan blue exclusion method
[PMID: 22014549]
CCRF-CEM IC50
14.3 μM
Compound: AZT
Cytotoxicity against human CEM cells after 6 days
Cytotoxicity against human CEM cells after 6 days
[PMID: 17158051]
CCRF-CEM IC50
14.3 μM
Compound: AZT
Cytotoxicity against Homo sapiens (human) CEM cells after 5 days celltiter 96 aqueous assay
Cytotoxicity against Homo sapiens (human) CEM cells after 5 days celltiter 96 aqueous assay
10.1007/s00044-011-9912-x
CCRF-CEM IC50
191 μM
Compound: AZT
Ability to reduce viable cell number on HIV-1-infected CEM cells in mice after intraperitoneal administration
Ability to reduce viable cell number on HIV-1-infected CEM cells in mice after intraperitoneal administration
[PMID: 8627600]
CCRF-CEM CC50
23.04 μM
Compound: AZT
Cytotoxicity against human CEM cells expressing green fluorescent protein by MTT assay
Cytotoxicity against human CEM cells expressing green fluorescent protein by MTT assay
[PMID: 20598537]
CCRF-CEM CC50
24 μM
Compound: AZT
Cytotoxicity against human CEM cells expressing GFP after 48 to 72 hrs by MTT assay
Cytotoxicity against human CEM cells expressing GFP after 48 to 72 hrs by MTT assay
[PMID: 20350812]
CCRF-CEM CC50
24.06 μM
Compound: AZT
Cytotoxicity against human CEM cells expressing green fluorescent protein after 48 hrs by MTT assay
Cytotoxicity against human CEM cells expressing green fluorescent protein after 48 hrs by MTT assay
[PMID: 21295891]
CCRF-CEM CC50
24.06 μM
Compound: AZT
Cytotoxicity against GFP expressing human CEM cells after 48 to 72 hrs by MTT assay
Cytotoxicity against GFP expressing human CEM cells after 48 to 72 hrs by MTT assay
[PMID: 20137956]
CCRF-CEM CC50
24.1 μM
Compound: AZT
Cytotoxicity against human CEM-GFP cells after 48 hrs by MTT assay
Cytotoxicity against human CEM-GFP cells after 48 hrs by MTT assay
[PMID: 21227704]
CCRF-CEM CC50
35.6 μg/mL
Compound: AZT
compound tested for anti-HIV-1 activity by plaque reduction assay against HIV-1 in CEM cells
compound tested for anti-HIV-1 activity by plaque reduction assay against HIV-1 in CEM cells
[PMID: 9548818]
CCRF-CEM IC50
35.6 μM
Compound: AZT
Antiviral activity against HIV1 infected in human CEM cells assessed as protection against virus-induced cytopathic effect after 6 days by XTT assay
Antiviral activity against HIV1 infected in human CEM cells assessed as protection against virus-induced cytopathic effect after 6 days by XTT assay
[PMID: 20691339]
CCRF-CEM IC50
56.1 μM
Compound: AZT
Cytotoxicity against human CEM cells after 5 days by trypan blue assay
Cytotoxicity against human CEM cells after 5 days by trypan blue assay
[PMID: 21371895]
CCRF-CEM CC50
56.1 μM
Compound: AZT
Cytotoxicity against human CEM cells assessed as reduction in cell growth incubated for 5 days by CellTiter 96 AQueous One Solution cell proliferation assay
Cytotoxicity against human CEM cells assessed as reduction in cell growth incubated for 5 days by CellTiter 96 AQueous One Solution cell proliferation assay
[PMID: 26451771]
CCRF-CEM CC50
6 μM
Compound: n AZT
Concentration required to reduce the viability of mock-infected CEM cells by 50%
Concentration required to reduce the viability of mock-infected CEM cells by 50%
[PMID: 11714616]
CCRF-CEM IC50
7.7 μM
Compound: AZT
Antiviral activity against HIV1 infected in CEM cells after 72 hrs by GFP reporter gene assay
Antiviral activity against HIV1 infected in CEM cells after 72 hrs by GFP reporter gene assay
[PMID: 22549138]
CCRF-CEM CC50
86.2 μM
Compound: AZT
Cytotoxicity against human CEM cells after 2 to 4 days by MTT assay
Cytotoxicity against human CEM cells after 2 to 4 days by MTT assay
[PMID: 19596885]
CEM-c113 CC50
> 5 μM
Compound: AZT
Concentration required to reduce by 50% the viability of noninfected treated CEM-CL13 cells
Concentration required to reduce by 50% the viability of noninfected treated CEM-CL13 cells
[PMID: 9154976]
CEM-c113 EC50
0.006 μM
Compound: AZT
Effective concentration that reduces HIV-induced cytopathic effect by 50% was determined by MTT assay.
Effective concentration that reduces HIV-induced cytopathic effect by 50% was determined by MTT assay.
[PMID: 8385224]
CEM-SS IC50
> 0.1 μM
Compound: AZT
Cytotoxicity against human CEM-SS cells by MTS assay
Cytotoxicity against human CEM-SS cells by MTS assay
[PMID: 20086149]
CEM-SS CC50
> 1 μM
Compound: AZT, 3'-azidothymidine
Cytotoxicity against human CEM-SS cells assessed as cell viability after 6 days by MTS assay
Cytotoxicity against human CEM-SS cells assessed as cell viability after 6 days by MTS assay
[PMID: 24102161]
CEM-SS CC50
> 1 μM
Compound: AZT
Cytotoxicity against human CEM-SS cells by MTT assay
Cytotoxicity against human CEM-SS cells by MTT assay
[PMID: 20112915]
CEM-SS CC50
> 1 μM
Compound: AZT
Cytotoxicity against human CEM-SS cells assessed as cell viability by XTT assay
Cytotoxicity against human CEM-SS cells assessed as cell viability by XTT assay
[PMID: 21035347]
CEM-SS CC50
> 1 μM
Compound: AZT
Cytotoxic concentration required to reduce the viability of mock infected CEM-SS cells by 50%.
Cytotoxic concentration required to reduce the viability of mock infected CEM-SS cells by 50%.
[PMID: 9240351]
CEM-SS CC50
> 100 μM
Compound: AZT
Cytotoxicity against human CEM-SS cells by MTT assay
Cytotoxicity against human CEM-SS cells by MTT assay
[PMID: 19944610]
CEM-SS CC50
> 100 μM
Compound: AZT
Antiviral activity in CEM-SS cell line infected with HIV-1 and cytotoxic concentration required to reduce the viability of uninfected cells by 50%
Antiviral activity in CEM-SS cell line infected with HIV-1 and cytotoxic concentration required to reduce the viability of uninfected cells by 50%
[PMID: 7562927]
CEM-SS CC50
> 100 μM
Compound: AZT
Cytotoxic concentration required to reduce the viability of HIV-1 by 50% in CEM-SS cells
Cytotoxic concentration required to reduce the viability of HIV-1 by 50% in CEM-SS cells
[PMID: 12593658]
CEM-SS CC50
> 100 μM
Compound: 1, AZT
Cytotoxic conc. which reduces the cell viability of HIV-1 LAI infected T4 lymphoblastoid CEM-SS cells by 50%
Cytotoxic conc. which reduces the cell viability of HIV-1 LAI infected T4 lymphoblastoid CEM-SS cells by 50%
[PMID: 10821705]
CEM-SS CC50
> 1000 μM
Compound: AZT
Cytotoxicity against human CEM-SS cells assessed as reduction in cell viability incubated for 5 days by MTT assay
Cytotoxicity against human CEM-SS cells assessed as reduction in cell viability incubated for 5 days by MTT assay
[PMID: 33711763]
CEM-SS IC50
0.002 μM
Compound: AZT
Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 0.78 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA
Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 0.78 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA
[PMID: 20086149]
CEM-SS EC50
0.002 μM
Compound: AZT ; azidothymidine
Antiviral activity against HIV-1 RF infected in human CEM-SS cells assessed as inhibition of virus-induced cytopathic effect by XTT assay
Antiviral activity against HIV-1 RF infected in human CEM-SS cells assessed as inhibition of virus-induced cytopathic effect by XTT assay
[PMID: 27234889]
CEM-SS IC50
0.0024 μM
Compound: AZT
Antiviral activity against HIV1 LAI in human CEM-SS cells assessed as RT activity after 5 days by single passage assay
Antiviral activity against HIV1 LAI in human CEM-SS cells assessed as RT activity after 5 days by single passage assay
[PMID: 20112915]
CEM-SS IC50
0.0026 μM
Compound: Zidovudine (AZT)
Compound was tested for activity against HIV-1 by syncytial plaque assay performed in duplicate using CEM-SS cells
Compound was tested for activity against HIV-1 by syncytial plaque assay performed in duplicate using CEM-SS cells
[PMID: 9548815]
CEM-SS IC50
0.003 μM
Compound: AZT
Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 1.56 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA
Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 1.56 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA
[PMID: 20086149]
CEM-SS IC50
0.003 μM
Compound: AZT
Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 0.78 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay
Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 0.78 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay
[PMID: 20086149]
CEM-SS EC50
0.003 μM
Compound: AZT
Effective concentration required to inhibit the replication of HIV-1 by 50% in CEM-SS cells
Effective concentration required to inhibit the replication of HIV-1 by 50% in CEM-SS cells
[PMID: 12593658]
CEM-SS IC50
0.0031 μM
Compound: Zidovudine (AZT)
Antiviral activity against Human Immunodeficiency Virus by Reverse transcriptase assay in CEM-SS cells
Antiviral activity against Human Immunodeficiency Virus by Reverse transcriptase assay in CEM-SS cells
[PMID: 9548815]
CEM-SS EC50
0.004 μM
Compound: AZT
Effective concentration required for antiviral activity against HIV strain IIIB in CEM-SS cells by XTT assay
Effective concentration required for antiviral activity against HIV strain IIIB in CEM-SS cells by XTT assay
[PMID: 7932526]
CEM-SS IC50
0.004 μM
Compound: AZT
Antiviral activity against Human immunodeficiency virus 1 3B expressing nef protein infecting in CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay
Antiviral activity against Human immunodeficiency virus 1 3B expressing nef protein infecting in CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay
[PMID: 20086149]
CEM-SS IC50
0.0051 μM
Compound: AZT
Antiviral activity against HIV1 LAI infected in human CEM-SS cells assessed as inhibition of viral replication by MTT assay
Antiviral activity against HIV1 LAI infected in human CEM-SS cells assessed as inhibition of viral replication by MTT assay
[PMID: 19944610]
CEM-SS EC50
0.0053 μM
Compound: AZT, 3'-azidothymidine
Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells assessed as inhibition of virus-induced cytopathic effect after 6 days by MTS assay
Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells assessed as inhibition of virus-induced cytopathic effect after 6 days by MTS assay
[PMID: 24102161]
CEM-SS IC50
0.006 μM
Compound: AZT
Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 3.13 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA
Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 3.13 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA
[PMID: 20086149]
CEM-SS EC50
0.006 μM
Compound: AZT
Antiviral activity in CEM-SS cell line infected with HIV-1 and Concentration required to inhibit the replication of HIV-1 by 50% was determined
Antiviral activity in CEM-SS cell line infected with HIV-1 and Concentration required to inhibit the replication of HIV-1 by 50% was determined
[PMID: 7562927]
CEM-SS IC50
0.007 μM
Compound: AZT
Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 1.56 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay
Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 1.56 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay
[PMID: 20086149]
CEM-SS EC50
0.009 μM
Compound: AZT
Antiviral activity against HIV1 3B infected in human CEM-SS cells assessed as inhibition of viral replication after 6 days by XTT assay
Antiviral activity against HIV1 3B infected in human CEM-SS cells assessed as inhibition of viral replication after 6 days by XTT assay
[PMID: 20086159]
CEM-SS IC50
0.01 μM
Compound: AZT
Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 3.13 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay
Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 3.13 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay
[PMID: 20086149]
CEM-SS IC50
0.015 μM
Compound: AZT
Antiviral activity against Human immunodeficiency virus 1 D1 harboring Tyr127His mutation in nef protein infecting in CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay
Antiviral activity against Human immunodeficiency virus 1 D1 harboring Tyr127His mutation in nef protein infecting in CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay
[PMID: 20086149]
CEM-SS EC50
0.02 μM
Compound: AZT
Effective concentration required for 50% inhibition of viral replication by syncytium-forming assay carried out in CEM-SS cells
Effective concentration required for 50% inhibition of viral replication by syncytium-forming assay carried out in CEM-SS cells
10.1016/0960-894X(95)00260-Z
CEM-SS IC50
0.028 μM
Compound: AZT
Antiviral activity against Human immunodeficiency virus 1 A7 harboring Tyr127His mutation in nef protein infecting in CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay
Antiviral activity against Human immunodeficiency virus 1 A7 harboring Tyr127His mutation in nef protein infecting in CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay
[PMID: 20086149]
CEM-SS IC50
0.04 μM
Compound: AZT
Antiviral activity against Human immunodeficiency virus 1 H10 harboring Tyr127His, Gly140Glu, Glu149Lys, Asp174Asn and Arg178Lys mutations in nef protein infecting in CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporat
Antiviral activity against Human immunodeficiency virus 1 H10 harboring Tyr127His, Gly140Glu, Glu149Lys, Asp174Asn and Arg178Lys mutations in nef protein infecting in CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporat
[PMID: 20086149]
CEM-SS IC50
0.08 μM
Compound: AZT
Antiviral activity against Human immunodeficiency virus 1 A12 harboring Tyr127His, Asp174Asn and Arg178Lys mutations in nef protein infecting in CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay
Antiviral activity against Human immunodeficiency virus 1 A12 harboring Tyr127His, Asp174Asn and Arg178Lys mutations in nef protein infecting in CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay
[PMID: 20086149]
CEM-SS EC50
0.095 μM
Compound: AZT
Effective concentration required for antiviral activity against T cell line of CEM-SS cells of Human by XTT assay
Effective concentration required for antiviral activity against T cell line of CEM-SS cells of Human by XTT assay
[PMID: 7932526]
CEM-SS EC50
0.3 μM
Compound: AZT
Effective concentration required for 50% inhibition of viral replication by XTT cytoprotection assay carried out in CEM-SS cells
Effective concentration required for 50% inhibition of viral replication by XTT cytoprotection assay carried out in CEM-SS cells
10.1016/0960-894X(95)00260-Z
CEM-SS EC50
2 nM
Compound: 2, AZT
Antiviral activity against HIV-1 subtype 3B infected in CEM-SS cells assessed as inhibition of viral replication after 6 days by XTT assay
Antiviral activity against HIV-1 subtype 3B infected in CEM-SS cells assessed as inhibition of viral replication after 6 days by XTT assay
[PMID: 22858097]
CEM-SS IC50
5.6 μM
Compound: AZT
In vitro inhibition of CEM-SS cell growth by 50 %
In vitro inhibition of CEM-SS cell growth by 50 %
[PMID: 2016713]
CEM-TK(-) EC50
> 100 μM
Compound: AZT
Concentration required to protect CEM/TK cells against the cytopathicity of HIV-2 by 50%
Concentration required to protect CEM/TK cells against the cytopathicity of HIV-2 by 50%
[PMID: 11356105]
CEM-TK(-) CC50
> 1000 μM
Compound: AZT
Cytotoxicity against human CEM-TK(-) cells assessed as reduction in cell viability incubated for 5 days by MTT assay
Cytotoxicity against human CEM-TK(-) cells assessed as reduction in cell viability incubated for 5 days by MTT assay
[PMID: 33711763]
CEM-TK(-) CC50
> 200 μg/mL
Compound: AZT
Cytotoxic concentration which is required to reduce CEM/TK- cell viability by 50%.
Cytotoxic concentration which is required to reduce CEM/TK- cell viability by 50%.
[PMID: 9046339]
CEM-TK(+) EC50
> 100 μM
Compound: AZT
Antiviral activity in CEM/TK cell line infected with HIV-1 and Concentration required to inhibit the replication of HIV-1 by 50% was determined
Antiviral activity in CEM/TK cell line infected with HIV-1 and Concentration required to inhibit the replication of HIV-1 by 50% was determined
[PMID: 7562927]
CEM-TK(+) CC50
> 100 μM
Compound: AZT
Antiviral activity in CEM/TK cell line infected with HIV-1 and cytotoxic concentration required to reduce the viability of uninfected cells by 50%
Antiviral activity in CEM/TK cell line infected with HIV-1 and cytotoxic concentration required to reduce the viability of uninfected cells by 50%
[PMID: 7562927]
DU-145 IC50
34.45 μM
Compound: 13, AZT
Cytotoxicity against human DU145 cells after 48 hrs by SRB method
Cytotoxicity against human DU145 cells after 48 hrs by SRB method
[PMID: 25933593]
H9 IC50
< 0.0003 μM
Compound: AZT
Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 6.25 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA
Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 6.25 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA
[PMID: 20086149]
H9 IC50
< 0.0003 μM
Compound: AZT
Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 12.5 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay
Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 12.5 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay
[PMID: 20086149]
H9 IC50
< 0.0003 μM
Compound: AZT
Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 6.25 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay
Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 6.25 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay
[PMID: 20086149]
H9 IC50
> 0.1 μM
Compound: AZT
Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 50 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA
Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 50 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA
[PMID: 20086149]
H9 IC50
> 0.1 μM
Compound: AZT
Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 25 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA
Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 25 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA
[PMID: 20086149]
H9 IC50
> 0.1 μM
Compound: AZT
Cytotoxicity against human H9 cells by MTS assay
Cytotoxicity against human H9 cells by MTS assay
[PMID: 20086149]
H9 IC50
0.001 μM
Compound: AZT
Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 12.5 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA
Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 12.5 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA
[PMID: 20086149]
H9 EC50
0.001 μM
Compound: AZT
Antiviral activity against HIV1 3B in human H9 cells assessed as inhibition of virus-induced cytopathic effect by formazan-based conventional colorimetric technique
Antiviral activity against HIV1 3B in human H9 cells assessed as inhibition of virus-induced cytopathic effect by formazan-based conventional colorimetric technique
[PMID: 11430019]
H9 EC50
0.001 μM
Compound: AZT
Antiviral activity against HIV1 RF in human H9 cells assessed as inhibition of virus-induced cytopathic effect by formazan-based conventional colorimetric technique
Antiviral activity against HIV1 RF in human H9 cells assessed as inhibition of virus-induced cytopathic effect by formazan-based conventional colorimetric technique
[PMID: 11430019]
H9 EC50
0.002 μg/mL
Compound: AZT
Cytotoxicity against mock-infected human H9 cells after 4 days
Cytotoxicity against mock-infected human H9 cells after 4 days
[PMID: 8946749]
H9 IC50
0.002 μM
Compound: AZT
Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 25 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay
Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 25 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay
[PMID: 20086149]
H9 EC50
0.00289 μg/mL
Compound: AZT
Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral p24 antigen levels after 4 days by ELISA
Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral p24 antigen levels after 4 days by ELISA
[PMID: 11678650]
H9 EC50
0.009 μM
Compound: AZT
Evaluation for anti-HIV activity using T cell line (H9).
Evaluation for anti-HIV activity using T cell line (H9).
10.1016/S0960-894X(97)10108-1
H9 EC50
0.01 μM
Compound: AZT
Cytotoxicity against human H9 cells after 6 days by MTT assay
Cytotoxicity against human H9 cells after 6 days by MTT assay
[PMID: 20846868]
H9 EC50
0.012 μg/mL
Compound: AZT
Cytotoxicity against mock-infected human H9 cells after 4 days
Cytotoxicity against mock-infected human H9 cells after 4 days
[PMID: 9748372]
H9 EC50
0.012 μg/mL
Compound: AZT
Inhibitory concentration required to inhibit HIV replication in H9 lymphocytes growth by 50%
Inhibitory concentration required to inhibit HIV replication in H9 lymphocytes growth by 50%
[PMID: 10021911]
H9 EC50
0.015 μM
Compound: AZT
Anti-HIV activity against acutely infected H9 lymphocytes. Activity expressed as concentration of compound able to suppress HIV replication by 50%.
Anti-HIV activity against acutely infected H9 lymphocytes. Activity expressed as concentration of compound able to suppress HIV replication by 50%.
[PMID: 9804704]
H9 EC50
0.023 μM
Compound: AZT
Antiviral activity against HIV1 3B in H9 cells after 4 days by p24-antigen ELISA
Antiviral activity against HIV1 3B in H9 cells after 4 days by p24-antigen ELISA
[PMID: 17190445]
H9 IC50
0.027 μM
Compound: AZT
Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 50 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay
Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 50 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay
[PMID: 20086149]
H9 IC50
0.03 μM
Compound: AZT
In vitro Cytotoxic concentration which reduced HIV-1 LAV infected H9 cells by 50 percent
In vitro Cytotoxic concentration which reduced HIV-1 LAV infected H9 cells by 50 percent
[PMID: 1573638]
H9 EC50
0.037 μM
Compound: AZT
Anti-HIV activity was measured in H9-cells by MAGI assay
Anti-HIV activity was measured in H9-cells by MAGI assay
[PMID: 9804704]
H9 ED50
0.04 μg/mL
Compound: AZT
Effective dose required to inhibit virus replication growth by 50%
Effective dose required to inhibit virus replication growth by 50%
[PMID: 8642556]
H9 EC50
0.04 μM
Compound: AZT
Antiviral activity against HIV1 3B in human H9 cells assessed as inhibition of viral replication after 3 days by p24 antigen capture assay
Antiviral activity against HIV1 3B in human H9 cells assessed as inhibition of viral replication after 3 days by p24 antigen capture assay
[PMID: 8176401]
H9 EC50
0.04 μM
Compound: AZT
Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral replication after 3 days by p24 antigen capture assay
Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral replication after 3 days by p24 antigen capture assay
[PMID: 8158164]
H9 EC50
0.04 μM
Compound: AZT
Concentration of compound which inhibits virus replication of HIV by 50% (EC50 of 10 uM) in acutely infected H9 lymphocyte cells was determined
Concentration of compound which inhibits virus replication of HIV by 50% (EC50 of 10 uM) in acutely infected H9 lymphocyte cells was determined
10.1016/S0960-894X(01)81071-4
H9 EC50
0.044 μM
Compound: AZT
Antiviral activity against HIV1 3B infected in H9 cells assessed as inhibition of viral replication by p24 antigen ELISA
Antiviral activity against HIV1 3B infected in H9 cells assessed as inhibition of viral replication by p24 antigen ELISA
[PMID: 20187635]
H9 EC50
0.045 M
Compound: AZT
Concentration required to inhibit HIV-1 replication by 50% in acutely infected H9 lymphocytes
Concentration required to inhibit HIV-1 replication by 50% in acutely infected H9 lymphocytes
[PMID: 15149703]
H9 EC50
0.045 μg/mL
Compound: AZT
Antiviral activity against HIV1 3B infected in human H9 T cells after 4 days by ELISA
Antiviral activity against HIV1 3B infected in human H9 T cells after 4 days by ELISA
[PMID: 9917290]
H9 EC50
0.045 μM
Compound: AZT
Anti-HIV activity was evaluated for the concentration that inhibits viral replication by 50%
Anti-HIV activity was evaluated for the concentration that inhibits viral replication by 50%
10.1016/S0960-894X(97)10050-6
H9 EC50
0.045 μM
Compound: AZT
Anti-HIV activity was evaluated as the concentration required to inhibit HIV-1 replication in H9 lymphocyte cells by 50%
Anti-HIV activity was evaluated as the concentration required to inhibit HIV-1 replication in H9 lymphocyte cells by 50%
[PMID: 9873374]
H9 EC50
0.052 μM
Compound: AZT
Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral replication after 6 days by p24 antigen based assay
Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral replication after 6 days by p24 antigen based assay
[PMID: 20527972]
H9 IC50
1870 μM
Compound: AZT
Cytotoxicity against human H9 cells after 4 days
Cytotoxicity against human H9 cells after 4 days
[PMID: 17190445]
H9 IC50
1871 μM
Compound: AZT
Antiviral activity against HIV1 3B isolate replication in human H9 cells assessed as decrease in viral p24 level after 4 days
Antiviral activity against HIV1 3B isolate replication in human H9 cells assessed as decrease in viral p24 level after 4 days
[PMID: 11141100]
H9 IC50
1872 μM
Compound: AZT
Concentration required to inhibit uninfected H9 cell growth by 50%
Concentration required to inhibit uninfected H9 cell growth by 50%
[PMID: 14736256]
H9 CC50
1873 μM
Compound: AZT
Cytotoxicity against human H9 cells after 6 days by XTT assay
Cytotoxicity against human H9 cells after 6 days by XTT assay
[PMID: 20527972]
H9 IC50
1875 μM
Compound: AZT
Inhibitory activity against gorwth of uninfected H9 cell growth by 50%
Inhibitory activity against gorwth of uninfected H9 cell growth by 50%
10.1016/S0960-894X(97)10050-6
H9 IC50
1875 μM
Compound: AZT
Compound was evaluated for anti-HIV activity and the concentration that inhibits uninfected H9 cell growth by 50%
Compound was evaluated for anti-HIV activity and the concentration that inhibits uninfected H9 cell growth by 50%
[PMID: 9873504]
H9 IC50
1875 μM
Compound: AZT
Anti-HIV activity was evaluated as the concentration required to inhibit the growth of uninfected H9 lymphocyte cells by 50%
Anti-HIV activity was evaluated as the concentration required to inhibit the growth of uninfected H9 lymphocyte cells by 50%
[PMID: 9873374]
H9 IC50
1875 μM
Compound: AZT
Concentration required to inhibit uninfected H9 cell growth by 50%
Concentration required to inhibit uninfected H9 cell growth by 50%
[PMID: 15149703]
H9 IC50
1875 μM
Compound: AZT
Inhibitory concentration required to inhibit uninfected H9 cell growth by 50%
Inhibitory concentration required to inhibit uninfected H9 cell growth by 50%
[PMID: 11527717]
H9 IC50
2000 μg/mL
Compound: AZT
Inhibitory concentration required to inhibit uninfected growth of H9 lymphocytes by 50%
Inhibitory concentration required to inhibit uninfected growth of H9 lymphocytes by 50%
[PMID: 8642556]
H9 IC50
2000 μM
Compound: AZT
Cytotoxicity against human H9 cells after 3 days
Cytotoxicity against human H9 cells after 3 days
[PMID: 8176401]
H9 IC50
2000 μM
Compound: AZT
Cytotoxicity against human H9 cells after 3 days
Cytotoxicity against human H9 cells after 3 days
[PMID: 8158164]
H9 IC50
2000 μM
Compound: AZT
Concentration which inhibits uninfected cell growth of HIV by 50% (IC50>140 uM) in acutely infected H9 lymphocyte cells was determined
Concentration which inhibits uninfected cell growth of HIV by 50% (IC50>140 uM) in acutely infected H9 lymphocyte cells was determined
10.1016/S0960-894X(01)81071-4
H9 IC50
50 nM
Compound: AZT
Tested for the inhibitory activity against HIV-1 in H-9 cell lines assessed by syncytium formation and reverse transcriptase assay
Tested for the inhibitory activity against HIV-1 in H-9 cell lines assessed by syncytium formation and reverse transcriptase assay
10.1016/0960-894X(95)00306-E
H9 IC50
500 μg/mL
Compound: AZT
Antiviral activity against HIV1 3B in human H9 cells assessed as inhibition of p24 antigen production after 4 days by ELISA
Antiviral activity against HIV1 3B in human H9 cells assessed as inhibition of p24 antigen production after 4 days by ELISA
[PMID: 8946749]
H9 IC50
500 μg/mL
Compound: AZT
Antiviral activity against HIV1 3B in human H9 cells after 4 days by p24 antigen ELISA
Antiviral activity against HIV1 3B in human H9 cells after 4 days by p24 antigen ELISA
[PMID: 9748372]
H9 IC50
500 μg/mL
Compound: AZT
Concentration that inhibits uninfected H9 cell growth by 50%.
Concentration that inhibits uninfected H9 cell growth by 50%.
[PMID: 12729671]
H9 IC50
500 μg/mL
Compound: AZT
Inhibitory concentration required to inhibit uninfected H9 lymphocytic cell growth by 50%
Inhibitory concentration required to inhibit uninfected H9 lymphocytic cell growth by 50%
[PMID: 10021911]
H9 IC50
500 μM
Compound: AZT
Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral replication after 6 hrs by p24 antigen based assay
Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral replication after 6 hrs by p24 antigen based assay
[PMID: 20846868]
HEK-293T CC50
> 10 μM
Compound: AZT
Cytotoxicity against human 293T cells assessed as inhibition of cell proliferation by tetrazolium dye method
Cytotoxicity against human 293T cells assessed as inhibition of cell proliferation by tetrazolium dye method
[PMID: 17470654]
HEK-293T EC50
200 nM
Compound: AZT
Antiviral activity against multidrug-resistant HIV1 695-RT infected in HEK293T cells assessed as inhibition of viral replication after 4 days by beta-galactosidase reporter gene assay
Antiviral activity against multidrug-resistant HIV1 695-RT infected in HEK293T cells assessed as inhibition of viral replication after 4 days by beta-galactosidase reporter gene assay
[PMID: 22148316]
HEK-293T EC50
6 nM
Compound: AZT
Antiviral activity against multidrug-resistant HIV1 106-PR infected in HEK293T cells assessed as inhibition of viral replication after 4 days by beta-galactosidase reporter gene assay
Antiviral activity against multidrug-resistant HIV1 106-PR infected in HEK293T cells assessed as inhibition of viral replication after 4 days by beta-galactosidase reporter gene assay
[PMID: 22148316]
HeLa IC50
> 100 μM
Compound: AZT, Zidovudine
Cytotoxicity against human HeLa cells at 125 uM after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells at 125 uM after 48 hrs by MTT assay
[PMID: 17416522]
HeLa IC50
> 100 μM
Compound: AZT, Zidovudine
Cytotoxicity against human HeLa cells at 100 uM after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells at 100 uM after 48 hrs by MTT assay
[PMID: 17416522]
HeLa IC50
> 100 μM
Compound: AZT
Cytotoxicity against human HeLa cells by MTT assay
Cytotoxicity against human HeLa cells by MTT assay
[PMID: 22858300]
HeLa CC50
> 25 μM
Compound: Zidovudine
Cytotoxicity against mock-infected human HeLa cells by MTT assay
Cytotoxicity against mock-infected human HeLa cells by MTT assay
[PMID: 25682562]
HeLa CC50
> 270 μM
Compound: AZT
Cytotoxicity against human HeLa P4/R5 cells after 2 to 4 hrs by MTT assay
Cytotoxicity against human HeLa P4/R5 cells after 2 to 4 hrs by MTT assay
[PMID: 19596885]
HeLa EC50
> 374 μM
Compound: 2, AZT, Zidovudine
Cytotoxicity against human HeLa P4/R5 cells after 48 hrs by MTT assay
Cytotoxicity against human HeLa P4/R5 cells after 48 hrs by MTT assay
[PMID: 22352809]
HeLa EC50
0.002 μM
Compound: AZT
Tested in vitro against HIV-1 104pre from HeLa-CD4-LT4-beta gal-cells using MAGI assay
Tested in vitro against HIV-1 104pre from HeLa-CD4-LT4-beta gal-cells using MAGI assay
[PMID: 11087576]
HeLa EC50
0.009 μM
Compound: AZT
Compound was tested for Anti-HIV activity by plaque reduction assay with E89K virus in HT4-6C human CD4+ lymphocytes
Compound was tested for Anti-HIV activity by plaque reduction assay with E89K virus in HT4-6C human CD4+ lymphocytes
[PMID: 9258355]
HeLa EC50
0.013 μM
Compound: AZT
Compound was tested for Anti-HIV activity by plaque reduction assay with wild type HIV-1LAI virus in HT4-6C human CD4+ lymphocytes
Compound was tested for Anti-HIV activity by plaque reduction assay with wild type HIV-1LAI virus in HT4-6C human CD4+ lymphocytes
[PMID: 9258355]
HeLa IC50
0.04 μM
Compound: AZT
Antiviral activity against VSV-G pseudotyped HIV1 lentiviral particles infected in human HeLa cells incubated for 48 hrs by spectrofluorometry
Antiviral activity against VSV-G pseudotyped HIV1 lentiviral particles infected in human HeLa cells incubated for 48 hrs by spectrofluorometry
[PMID: 22858300]
HeLa IC50
10.77 μM
Compound: 3; AZT
Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
[PMID: 31400940]
HeLa IC50
10.77 μM
Compound: AZT
Cytotoxicity against human HeLa cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay
Cytotoxicity against human HeLa cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay
[PMID: 27501415]
HeLa EC50
10.8 μM
Compound: 2, AZT, Zidovudine
Antiviral activity against HIV1 3B infected in HeLa P4/R5 cells assessed as reduction of viral infection incubated for 2 hrs followed by incubated in drug-free medium for 46 hrs by single round infection beta-galactosidase reporter gene assay
Antiviral activity against HIV1 3B infected in HeLa P4/R5 cells assessed as reduction of viral infection incubated for 2 hrs followed by incubated in drug-free medium for 46 hrs by single round infection beta-galactosidase reporter gene assay
[PMID: 22352809]
HeLa EC50
14.2 μM
Compound: 2, AZT, Zidovudine
Antiviral activity against HIV1 BaL infected in HeLa P4/R5 cells assessed as reduction of viral infection incubated for 2 hrs followed by incubated in drug-free medium for 46 hrs by single round infection beta-galactosidase reporter gene assay
Antiviral activity against HIV1 BaL infected in HeLa P4/R5 cells assessed as reduction of viral infection incubated for 2 hrs followed by incubated in drug-free medium for 46 hrs by single round infection beta-galactosidase reporter gene assay
[PMID: 22352809]
HeLa EC50
2.9 μM
Compound: AZT
Compound was tested for Anti-HIV activity by plaque reduction assay with A018-post virus in HT4-6C human CD4+ lymphocytes
Compound was tested for Anti-HIV activity by plaque reduction assay with A018-post virus in HT4-6C human CD4+ lymphocytes
[PMID: 9258355]
HeLa IC50
65.46 μM
Compound: 13, AZT
Cytotoxicity against human HeLa cells after 48 hrs by SRB method
Cytotoxicity against human HeLa cells after 48 hrs by SRB method
[PMID: 25933593]
HepG2 IC50
> 400 μM
Compound: Azidothymidine
Antiproliferative activity against human HepG2 cells by MTT assay
Antiproliferative activity against human HepG2 cells by MTT assay
[PMID: 31546197]
HepG2 IC50
> 479 μM
Compound: AZT; Zidovudine
Cytotoxicity against human HepG2 cells assessed as growth inhibition measured after 3 days by MTT assay
Cytotoxicity against human HepG2 cells assessed as growth inhibition measured after 3 days by MTT assay
[PMID: 27342752]
HepG2 IC50
13.03 μM
Compound: 3; AZT
Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
[PMID: 31400940]
HL-60 IC50
96 μM
Compound: AZT
Cytotoxicity was tested in HL60 cells by the trypan blue exclusion assay.
Cytotoxicity was tested in HL60 cells by the trypan blue exclusion assay.
[PMID: 1695683]
HOS IC50
1.4 μM
Compound: AZT
Inhibition of HIV1 wild type reverse transcriptase-mediated viral DNA synthesis in human HOS cells assessed as luciferase activity treated 3 hrs before infection measured after 48 hrs by luminescence assay
Inhibition of HIV1 wild type reverse transcriptase-mediated viral DNA synthesis in human HOS cells assessed as luciferase activity treated 3 hrs before infection measured after 48 hrs by luminescence assay
[PMID: 19678643]
HOS IC50
20.1 μM
Compound: AZT
Inhibition of HIV1 reverse transcriptase M41L/D67N/K70R/T215Y/K219Q mutant-mediated viral DNA synthesis in human HOS cells assessed as luciferase activity treated 3 hrs before infection measured after 48 hrs by luminescence assay
Inhibition of HIV1 reverse transcriptase M41L/D67N/K70R/T215Y/K219Q mutant-mediated viral DNA synthesis in human HOS cells assessed as luciferase activity treated 3 hrs before infection measured after 48 hrs by luminescence assay
[PMID: 19678643]
HOS IC50
3.6 μM
Compound: AZT
Inhibition of HIV1 reverse transcriptase M184V mutant-mediated viral DNA synthesis in human HOS cells assessed as luciferase activity treated 3 hrs before infection measured after 48 hrs by luminescence assay
Inhibition of HIV1 reverse transcriptase M184V mutant-mediated viral DNA synthesis in human HOS cells assessed as luciferase activity treated 3 hrs before infection measured after 48 hrs by luminescence assay
[PMID: 19678643]
HOS IC50
39.6 μM
Compound: AZT
Inhibition of HIV1 reverse transcriptase SSGR/T215Y mutant-mediated viral DNA synthesis in human HOS cells assessed as luciferase activity treated 3 hrs before infection measured after 48 hrs by luminescence assay
Inhibition of HIV1 reverse transcriptase SSGR/T215Y mutant-mediated viral DNA synthesis in human HOS cells assessed as luciferase activity treated 3 hrs before infection measured after 48 hrs by luminescence assay
[PMID: 19678643]
Huh-7 EC50
> 10 μM
Compound: AZT
Antiviral activity against Hepatitis C virus infected in human HuH7 cells assessed as decrease in viral RNA level after 96 hrs by RT-PCR
Antiviral activity against Hepatitis C virus infected in human HuH7 cells assessed as decrease in viral RNA level after 96 hrs by RT-PCR
[PMID: 22014549]
Huh-7 CC50
> 10 μM
Compound: AZT
Cytotoxicity against human HuH7 cells assessed as reduction in rRNA levels at 120 hrs by RT-PCR analysis
Cytotoxicity against human HuH7 cells assessed as reduction in rRNA levels at 120 hrs by RT-PCR analysis
[PMID: 23623492]
Huh-7 CC50
> 10 μM
Compound: AZT
Cytotoxicity against human HuH7 cells assessed as reduction of 50% rRNA level after 96 hrs
Cytotoxicity against human HuH7 cells assessed as reduction of 50% rRNA level after 96 hrs
[PMID: 22014549]
JM1 CC50
> 1000 μM
Compound: AZT
Concentration required to reduce cell viability of JM cells by 50%
Concentration required to reduce cell viability of JM cells by 50%
10.1016/0960-894X(96)00443-X
Jurkat EC50
0.09 μM
Compound: AZT
Antiviral activity against HIV1 pseudovirus infected in Jurkat cells coexpressing GFP assessed as viral growth inhibition incubated for 2 to 8 hrs prior to infection measured after 48 hrs by flow cytofluorimetric analysis
Antiviral activity against HIV1 pseudovirus infected in Jurkat cells coexpressing GFP assessed as viral growth inhibition incubated for 2 to 8 hrs prior to infection measured after 48 hrs by flow cytofluorimetric analysis
[PMID: 22954898]
Jurkat IC50
120 nM
Compound: AZT
Antiviral activity against HIV1 Env-pseudovirus infected in human Jurkat E6-1 cells after 2 days by luciferase assay
Antiviral activity against HIV1 Env-pseudovirus infected in human Jurkat E6-1 cells after 2 days by luciferase assay
[PMID: 21414776]
KB IC50
> 400 μM
Compound: Azidothymidine
Antiproliferative activity against human KB cells by MTT assay
Antiproliferative activity against human KB cells by MTT assay
[PMID: 31546197]
KB IC50
3.12 μg/mL
Compound: AZT, Zidovudine
Cytotoxicity against human KB cells assessed as cell survival after 72 hrs by sulforhodamine B colorimetric assay
Cytotoxicity against human KB cells assessed as cell survival after 72 hrs by sulforhodamine B colorimetric assay
[PMID: 21945463]
KB IC50
9.77 μM
Compound: 3; AZT
Cytotoxicity in human KB cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
Cytotoxicity in human KB cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
[PMID: 31400940]
KB IC50
9.77 μM
Compound: AZT
Cytotoxicity against human KB cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay
Cytotoxicity against human KB cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay
[PMID: 27501415]
KB 3-1 IC50
9.17 μM
Compound: AZT, Zidovudine
Cytotoxicity against human KB-3-1 cells after 72 hrs by MTT assay
Cytotoxicity against human KB-3-1 cells after 72 hrs by MTT assay
[PMID: 25440502]
M EC50
0.015 μM
Compound: AZT
Effective concentration required for antiviral activity against M cell line of macrophage cells of Human by XTT assay
Effective concentration required for antiviral activity against M cell line of macrophage cells of Human by XTT assay
[PMID: 7932526]
MCF7 IC50
13.74 μM
Compound: AZT, Zidovudine
Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
[PMID: 25440502]
MCF7 IC50
2.6 μg/mL
Compound: AZT, Zidovudine
Cytotoxicity against human MCF7 cells assessed as cell survival after 72 hrs by sulforhodamine B colorimetric assay
Cytotoxicity against human MCF7 cells assessed as cell survival after 72 hrs by sulforhodamine B colorimetric assay
[PMID: 21945463]
MCF7 IC50
34.97 μM
Compound: 13, AZT
Cytotoxicity against human MCF7 cells after 48 hrs by SRB method
Cytotoxicity against human MCF7 cells after 48 hrs by SRB method
[PMID: 25933593]
MCF7 IC50
7.67 μM
Compound: AZT
Cytotoxicity against human MCF7 cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay
[PMID: 27501415]
MOLT-3 CC50
12.1 μM
Compound: AZT
Cytotoxicity against human MOLT3 cells by MTS assay
Cytotoxicity against human MOLT3 cells by MTS assay
[PMID: 22549138]
MOLT-3 CC50
3.24 μg/mL
Compound: AZT
Cytotoxicity against human MOLT3 cells after 24 hrs by MTS assay
Cytotoxicity against human MOLT3 cells after 24 hrs by MTS assay
[PMID: 21334901]
MOLT-4 EC50
> 10 μM
Compound: AZT
Antiviral activity against HIV1 3B infected in MOLT-4/3B cells assessed as inhibition of mature virus release measured after 4 days of infection by RT assay
Antiviral activity against HIV1 3B infected in MOLT-4/3B cells assessed as inhibition of mature virus release measured after 4 days of infection by RT assay
[PMID: 18316521]
MT2 CC50
> 200 μM
Compound: AZT
Cytotoxicity against human MT2 cells by MTT assay
Cytotoxicity against human MT2 cells by MTT assay
[PMID: 20542430]
MT2 CC50
> 200 μM
Compound: AZT, zidovudine
Cytotoxicity against human MT2 cells after 5 days
Cytotoxicity against human MT2 cells after 5 days
[PMID: 19179082]
MT2 CC50
≥ 25 μM
Compound: AZT
Cytotoxicity against human MT2 cells by MTT assay
Cytotoxicity against human MT2 cells by MTT assay
[PMID: 23570720]
MT2 EC50
0.0012 μM
Compound: AZT
Antiviral activity against HIV1 subtype B-3B infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
Antiviral activity against HIV1 subtype B-3B infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
[PMID: 18316521]
MT2 EC50
0.0029 μM
Compound: AZT
Antiviral activity against HIV1 subtype B-RF infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
Antiviral activity against HIV1 subtype B-RF infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
[PMID: 18316521]
MT2 EC50
0.003 μM
Compound: AZT
Effective concentration required for antiviral activity against HIV strain IIIB in MT-2 cells by XTT assay
Effective concentration required for antiviral activity against HIV strain IIIB in MT-2 cells by XTT assay
[PMID: 7932526]
MT2 EC50
0.0038 μM
Compound: AZT
Antiviral activity against HIV1 subtype B-LAI infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
Antiviral activity against HIV1 subtype B-LAI infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
[PMID: 18316521]
MT2 EC50
0.0049 μM
Compound: AZT
Antiviral activity against HIV1 subtype B-NL4-3 infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
Antiviral activity against HIV1 subtype B-NL4-3 infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
[PMID: 18316521]
MT2 EC50
0.0063 μM
Compound: AZT
Antiviral activity against HIV1 subtype B-SF-2 infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
Antiviral activity against HIV1 subtype B-SF-2 infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
[PMID: 18316521]
MT2 EC50
0.008 μM
Compound: AZT
Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA
Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA
[PMID: 18316521]
MT2 EC50
0.01 μM
Compound: AZT
Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA
Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA
[PMID: 18316521]
MT2 EC50
0.014 μM
Compound: AZT
Antiviral activity against HIV1 subtype B-HXB2 infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
Antiviral activity against HIV1 subtype B-HXB2 infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
[PMID: 18316521]
MT2 EC50
0.016 μM
Compound: AZT
Antiviral activity against pseudotype HIV1 NL-RLuc infected in human MT2 cells measured on day 5 postinfection by luciferase reporter gene assay
Antiviral activity against pseudotype HIV1 NL-RLuc infected in human MT2 cells measured on day 5 postinfection by luciferase reporter gene assay
[PMID: 18316521]
MT2 EC50
0.018 μM
Compound: AZT
Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA
Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA
[PMID: 18316521]
MT2 EC50
0.02 μM
Compound: AZT
Inhibition of HIV1 LAI replication in MT2 cells by cytopathic effect assay
Inhibition of HIV1 LAI replication in MT2 cells by cytopathic effect assay
[PMID: 17004726]
MT2 EC50
0.027 μM
Compound: AZT
Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay
Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay
[PMID: 18316521]
MT2 EC50
0.034 μM
Compound: AZT
Antiviral activity against HIV1 3B infected in human MT2 cells assessed as inhibition of viral replication treated 1 day after infection measured on after 4 days postinfection by p24 antigen ELISA
Antiviral activity against HIV1 3B infected in human MT2 cells assessed as inhibition of viral replication treated 1 day after infection measured on after 4 days postinfection by p24 antigen ELISA
[PMID: 20329730]
MT2 EC50
0.038 μM
Compound: AZT
Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay
Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay
[PMID: 18316521]
MT2 EC50
0.043 μM
Compound: AZT
Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA
Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA
[PMID: 18316521]
MT2 EC50
0.044 μM
Compound: AZT
Antiviral activity against HIV1 3B infected in human MT2 cells assessed as inhibition of viral p24 antigen production after 6 days by ELISA
Antiviral activity against HIV1 3B infected in human MT2 cells assessed as inhibition of viral p24 antigen production after 6 days by ELISA
[PMID: 20537902]
MT2 IC50
0.047 μM
Compound: AZT
Antiviral activity against HIV1 bearing VSV glycoprotein infected in human MT2 cells assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay
Antiviral activity against HIV1 bearing VSV glycoprotein infected in human MT2 cells assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay
[PMID: 20542430]
MT2 IC50
0.0493 μM
Compound: AZT
Antiviral activity against HIV1 3B infected in human MT2 cells assessed as protection against virus-induced cytopathogenicity by MTT assay
Antiviral activity against HIV1 3B infected in human MT2 cells assessed as protection against virus-induced cytopathogenicity by MTT assay
[PMID: 20728351]
MT2 EC50
0.051 μM
Compound: AZT
Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA
Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA
[PMID: 18316521]
MT2 EC50
0.054 μM
Compound: AZT
Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay
Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay
[PMID: 18316521]
MT2 EC50
0.056 μM
Compound: AZT
Antiviral activity against HIV1 3B infected in human MT2 cells assessed as p24 antigen level after 4 days by ELISA
Antiviral activity against HIV1 3B infected in human MT2 cells assessed as p24 antigen level after 4 days by ELISA
[PMID: 19388685]
MT2 ED50
0.07 μM
Compound: AZT
Effective antiviral dose required to block the spread of HIV-1 IIIb infection in MT-2 cells by monitoring the formation of syncytia
Effective antiviral dose required to block the spread of HIV-1 IIIb infection in MT-2 cells by monitoring the formation of syncytia
[PMID: 7512142]
MT2 EC50
0.075 μM
Compound: AZT
Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA
Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA
[PMID: 18316521]
MT2 EC50
0.087 μM
Compound: AZT
Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay
Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay
[PMID: 18316521]
MT2 EC50
0.117 μM
Compound: AZT
Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay
Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay
[PMID: 18316521]
MT2 EC50
0.144 μM
Compound: AZT
Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay
Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay
[PMID: 18316521]
MT2 EC50
0.16 μM
Compound: AZT, zidovudine
Antiviral activity against HIV1 3a infected human MT2 cells assessed as inhibition of viral-induced cytopathic effect after 3 days by XTT assay
Antiviral activity against HIV1 3a infected human MT2 cells assessed as inhibition of viral-induced cytopathic effect after 3 days by XTT assay
[PMID: 19179082]
MT2 EC50
0.16 μM
Compound: 3
Inhibition of virus-induced cytopathic effect in wild type HIV 3a infected MT2 cells after 5 days
Inhibition of virus-induced cytopathic effect in wild type HIV 3a infected MT2 cells after 5 days
[PMID: 17562366]
MT2 IC50
0.16 μM
Compound: AZT
In vitro Cytotoxic concentration which reduced HIV-1 LAV infected MT-2 cells by 50 percent
In vitro Cytotoxic concentration which reduced HIV-1 LAV infected MT-2 cells by 50 percent
[PMID: 1573638]
MT2 IC50
0.2 μM
Compound: AZT
In vitro Cytotoxic concentration which reduced H 112-2(pre-AZT) infected MT-2 cells by 50 percent
In vitro Cytotoxic concentration which reduced H 112-2(pre-AZT) infected MT-2 cells by 50 percent
[PMID: 1573638]
MT2 EC50
0.209 μM
Compound: AZT
Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA
Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA
[PMID: 18316521]
MT2 IC50
0.22 μM
Compound: AZT
In vitro Cytotoxic concentration which reduced G 762-3(pre-AZT) infected MT-2 cells by 50 percent
In vitro Cytotoxic concentration which reduced G 762-3(pre-AZT) infected MT-2 cells by 50 percent
[PMID: 1573638]
MT2 EC50
0.223 μM
Compound: AZT
Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay
Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay
[PMID: 18316521]
MT2 EC50
0.249 μM
Compound: AZT
Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA
Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA
[PMID: 18316521]
MT2 EC50
0.302 μM
Compound: AZT
Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay
Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay
[PMID: 18316521]
MT2 IC50
10 μM
Compound: AZT
In vitro Cytotoxic concentration which reduced G 691-2(post-AZT) infected MT-2 cells by 50 percent
In vitro Cytotoxic concentration which reduced G 691-2(post-AZT) infected MT-2 cells by 50 percent
[PMID: 1573638]
MT2 CC50
150 μM
Compound: AZT
Cytotoxicity against human MT2 cells after 2 to 4 days by MTT assay
Cytotoxicity against human MT2 cells after 2 to 4 days by MTT assay
[PMID: 19596885]
MT2 IC50
1870 μM
Compound: AZT
Cytotoxicity against human MT2 cells by XTT assay
Cytotoxicity against human MT2 cells by XTT assay
[PMID: 20329730]
MT2 CC50
1870 μM
Compound: AZT
Cytotoxicity against human MT2 cells by XTT assay
Cytotoxicity against human MT2 cells by XTT assay
[PMID: 19388685]
MT2 IC50
1870 μM
Compound: AZT
Cytotoxicity against MT2 cells by XTT assay
Cytotoxicity against MT2 cells by XTT assay
[PMID: 17935987]
MT2 IC50
1872 μM
Compound: AZT
Cytotoxicity against human MT2 cells after 6 days by XTT assay
Cytotoxicity against human MT2 cells after 6 days by XTT assay
[PMID: 20537902]
MT2 IC50
31 μM
Compound: AZT
In vitro Cytotoxic concentration which reduced G 910-6p2 (post-AZT) infected MT-2 cells by 50 percent
In vitro Cytotoxic concentration which reduced G 910-6p2 (post-AZT) infected MT-2 cells by 50 percent
[PMID: 1573638]
MT2 EC50
47 nM
Compound: AZT
Antiviral activity against vesicular stomatitis virus G-pseudotyped Human immunodeficiency virus 1 NL4-3 infected in human MT2 cells assessed as inhibition of viral replication after 48 hrs by luciferase activity reporter gene assay
Antiviral activity against vesicular stomatitis virus G-pseudotyped Human immunodeficiency virus 1 NL4-3 infected in human MT2 cells assessed as inhibition of viral replication after 48 hrs by luciferase activity reporter gene assay
[PMID: 21745701]
MT4 CC50
> 0.00748 μM
Compound: AZT
Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay
Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay
[PMID: 28481112]
MT4 CC50
> 0.1 μM
Compound: AZT
Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 3 days by CytoTox-Glo assay
Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 3 days by CytoTox-Glo assay
[PMID: 26756779]
MT4 CC50
> 0.37 μM
Compound: AZT
Cytotoxicity against human MT4 cells treated for 3 days measured by Celltiter-glo luminescent assay
Cytotoxicity against human MT4 cells treated for 3 days measured by Celltiter-glo luminescent assay
[PMID: 33214842]
MT4 CC50
> 0.37 μM
Compound: AZT
Cytotoxicity against human MT4 cells measured after 3 days by CytoTox-Glo assay
Cytotoxicity against human MT4 cells measured after 3 days by CytoTox-Glo assay
[PMID: 31184480]
MT4 CC50
> 0.4 μM
Compound: AZT
Cytotoxicity against human MT4 cells after 3 days by CytoTox-Glo assay
Cytotoxicity against human MT4 cells after 3 days by CytoTox-Glo assay
[PMID: 30031972]
MT4 CC50
> 0.5 μM
Compound: AZT
Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 6 days by XTT tetrazolium dye-based assay
Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 6 days by XTT tetrazolium dye-based assay
[PMID: 28682067]
MT4 CC50
> 1 μg/mL
Compound: AZT
Cytotoxicity against human MT4 cells after 5 days by MTT assay
Cytotoxicity against human MT4 cells after 5 days by MTT assay
[PMID: 22652226]
MT4 CC50
> 1 μM
Compound: AZT
Cytotoxicity against human MT4 cells by MTT assay
Cytotoxicity against human MT4 cells by MTT assay
[PMID: 20112915]
MT4 CC50
> 100 μM
Compound: AZT
Cytotoxicity against human MT4 cells after 4 days by MTT assay
Cytotoxicity against human MT4 cells after 4 days by MTT assay
[PMID: 23916148]
MT4 CC50
> 100 μM
Compound: AZT
Cytotoxicity against human MT4 cells after 5 days by MTT assay
Cytotoxicity against human MT4 cells after 5 days by MTT assay
[PMID: 22277590]
MT4 CC50
> 100 μM
Compound: AZT
Cytotoxicity against human MT4 cells by MTT assay
Cytotoxicity against human MT4 cells by MTT assay
[PMID: 26094944]
MT4 CC50
> 100 μM
Compound: AZT
Cytotoxicity against human MT4 cells by MTT assay
Cytotoxicity against human MT4 cells by MTT assay
[PMID: 19944610]
MT4 CC50
> 100 μM
Compound: AZT
Cytotoxicity against human MT4 cells by MTT assay
Cytotoxicity against human MT4 cells by MTT assay
[PMID: 17548498]
MT4 CC50
> 100 μM
Compound: AZT
Tested in vitro against MT-4 cells using MTT assay
Tested in vitro against MT-4 cells using MTT assay
[PMID: 11087576]
MT4 CC50
> 100 μM
Compound: AZT
Cytotoxicity against human MT4 cells by MTT assay in presence of 5 uM of chloroquine
Cytotoxicity against human MT4 cells by MTT assay in presence of 5 uM of chloroquine
[PMID: 26094944]
MT4 CC50
> 100 μM
Compound: AZT
Cytotoxic concentration required to reduce the viability of HIV-1 by 50% MT-4 cells
Cytotoxic concentration required to reduce the viability of HIV-1 by 50% MT-4 cells
[PMID: 12593658]
MT4 CC50
> 100 μM
Compound: 1, AZT
Cytotoxic conc. which reduces the cell viability of HIV-1 IIIB infected T4 lymphoblastoid MT-4 cells by 50%
Cytotoxic conc. which reduces the cell viability of HIV-1 IIIB infected T4 lymphoblastoid MT-4 cells by 50%
[PMID: 10821705]
MT4 CC50
> 15 μM
Compound: AZT
Cytotoxicity against human MT4 cells incubated for 3 days by CellTiter-Glo luminescent assay
Cytotoxicity against human MT4 cells incubated for 3 days by CellTiter-Glo luminescent assay
[PMID: 31860304]
MT4 CC50
> 15 μM
Compound: Zidovudine
Cytotoxicity against human MT4 cells assessed as inhibition of cell viability by measuring reduction in absorbance at OD540 by MTT assay
Cytotoxicity against human MT4 cells assessed as inhibition of cell viability by measuring reduction in absorbance at OD540 by MTT assay
[PMID: 31767136]
MT4 CC50
> 18710 nM
Compound: AZT
Cytotoxicity against mock-infected human MT4 cells measured after 5 days by MTT assay
Cytotoxicity against mock-infected human MT4 cells measured after 5 days by MTT assay
[PMID: 22712652]
MT4 CC50
> 2 μM
Compound: AZT
Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
[PMID: 34583311]
MT4 CC50
> 2.5 μg/mL
Compound: Zidovudine
Cytotoxicity against Homo sapiens (human) MT4 cells after 4 days by MTT assay
Cytotoxicity against Homo sapiens (human) MT4 cells after 4 days by MTT assay
10.1007/s00044-011-9664-7
MT4 CC50
> 20 μM
Compound: AZT
Concentration required to reduce the viability of mock-infected MT-4 cells by 50%
Concentration required to reduce the viability of mock-infected MT-4 cells by 50%
10.1016/S0960-894X(97)00340-5
MT4 CC50
> 20 μM
Compound: AZT
Concentration required to reduce the viability of mock-infected MT-4 cells by 50%
Concentration required to reduce the viability of mock-infected MT-4 cells by 50%
[PMID: 8558522]
MT4 CC50
> 20 μM
Compound: AZT
Compound dose required to reduce the viability of mock-infected cells by 50%
Compound dose required to reduce the viability of mock-infected cells by 50%
[PMID: 7650679]
MT4 CC50
> 2000 nM
Compound: AZT
Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay
Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay
[PMID: 29353724]
MT4 CC50
> 25 μg/mL
Compound: Azidothymidine
Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 3 to 6 days by MTS assay
Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 3 to 6 days by MTS assay
[PMID: 26707844]
MT4 CC50
> 25 μg/mL
Compound: Zidovudine
Cytotoxicity against Homo sapiens (human) MT4 cells after 4 days by MTT assay
Cytotoxicity against Homo sapiens (human) MT4 cells after 4 days by MTT assay
10.1007/s00044-011-9776-0
MT4 CC50
> 25 μg/mL
Compound: Zidovudine